SGYP Synergy Pharmaceuticals, Inc.

4.11
+0  (0%)
Previous Close 4.10
Open 4.10
Price To book 22.16
Market Cap 917.00M
Shares 223,115,000
Volume 3,451,453
Short Ratio 8.86
Av. Daily Volume 6,792,070

SEC filingsSee all SEC filings

  1. PRE 14A - Other preliminary proxy statements 17765242
  2. 8-K - Current report 17764611
  3. 8-K - Current report 17757036
  4. 8-K - Current report 17744540
  5. 8-K - Current report 17714213

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from first and second trials met primary endpoints - December 9 and 22, 2016. sNDA filing submitted - announced March 27, 2017.
Trulance (plecanatide)
Constipation-predominant irritable bowel syndrome (IBS-C)
Approved January 19, 2017.
Trulance (plecanatide)
Chronic idiopathic constipation (CIC)
Phase 1b data released January 2016. Phase 2 planned.
Dolcanatide
Mild-to-moderate ulcerative colitis

Latest News

  1. Synergy Pharmaceuticals Appoints Gary G. Gemignani as Chief Financial Officer
  2. Biotech Movers: Synergy, Biogen, Insys
  3. Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents
  4. Synergy Pharmaceuticals Announces Issuance of Three New Patents Expected to Extend TRULANCE™ (Plecanatide) Patent Protection Until 2032
  5. ($$) Overheard
  6. Drug Company's New Poop Emojis Make a Splash
  7. Trevena, Synergy Lead Biotech Movers
  8. Synergy Pharmaceuticals Launches the Poop Troop, the First Emoji Keyboard Designed to Support Dialogue Around Chronic Idiopathic Constipation (CIC)
  9. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Synergy Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  10. Synergy Pharmaceuticals Submits Supplemental New Drug Application (sNDA) for TRULANCE™ (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
  11. Synergy Pharmaceuticals to Present at Oppenheimer 27th Annual Healthcare Conference
  12. Synergy Pharmaceuticals: Approval, Now What?
  13. CORRECTING and REPLACING Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update
  14. Synergy Pharma reports 4Q loss
  15. Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update
  16. Did 50 Salespeople Leave Valeant? Wells Fargo Investigates
  17. Synergy Pharmaceuticals to Present at Leerink Partners 6th Annual Global Healthcare Conference
  18. Pivotal Phase 3 Data Results for TRULANCE™ (plecanatide) in the Treatment of Chronic Idiopathic Constipation (CIC) Published in American Journal of Gastroenterology
  19. Price For Synergy Pharmaceuticals Inc (SGYP) Public Offering Announced
  20. Why Synergy Pharmaceuticals Shares Fell 14.6% Today

SEC Filings

  1. PRE 14A - Other preliminary proxy statements 17765242
  2. 8-K - Current report 17764611
  3. 8-K - Current report 17757036
  4. 8-K - Current report 17744540
  5. 8-K - Current report 17714213
  6. 8-K - Current report 17703902
  7. 8-K - Current report 17687083
  8. 8-K - Current report 17658655
  9. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17655390
  10. 8-K - Current report 17613402